InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (1 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
1
T+90 hit rate
50%
T+90 mean return
-1.4%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the complete record of transactions filed by McFarlane Neil F., Chairman & CEO. Officer active across 3 companies, notably Adamas Pharmaceuticals Inc. Cumulatively, 10 disclosures have been logged. Split: 0 buy · 1 sell. Total volume traded: €463k. History available since 24 November 2021. The latest transaction was disclosed on 13 February 2025 (Cession). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to McFarlane Neil F.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations10 total
37,500 sharesCommon StockSEC:0001681098-26-000004:0
233,334 sharesCommon StockSEC:0001681098-26-000002:0
50,000 sharesCommon StockSEC:0001681098-25-000005:0
61,273 shares@ US$7.8571100.0% of flowCommon StockSEC:0001437749-25-004067:0
233,333 sharesCommon StockSEC:0001437749-25-002623:0
7,693 shares0Common StockSEC:0001062993-24-010541:0
9,792 shares0Common StockSEC:0001062993-23-011820:0
14,035 shares0Common StockSEC:0001062993-22-013303:0
17,845 shares0Common StockSEC:0001062993-22-010000:0
75,000 shares0Common StockSEC:0001328143-21-000093:0
10 of 10 declarations
About McFarlane Neil F.
Neil F. McFarlane is the Chief Executive Officer of Adamas Pharmaceuticals Inc and Collegium Pharmaceutical, Inc. As CEO, he leads both companies in the biopharmaceutical sector. McFarlane is responsible for the overall strategy and innovation in developing medical treatments. Under his leadership, the companies are committed to providing high-quality healthcare solutions.
